{"id":"before-cpb-tranexamic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Thromboembolic events"},{"rate":null,"effect":"Seizures"},{"rate":null,"effect":"Renal dysfunction"},{"rate":null,"effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. When administered before cardiopulmonary bypass (CPB), it reduces excessive bleeding and the need for blood transfusions during and after cardiac surgery by stabilizing formed clots.","oneSentence":"Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss during cardiopulmonary bypass surgery.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:16.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of blood loss and transfusion requirements in patients undergoing cardiopulmonary bypass surgery"}]},"trialDetails":[{"nctId":"NCT07005661","phase":"PHASE2, PHASE3","title":"Use of PRP in Open Surgery for Type A Aortic Dissection","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-06-30","conditions":"Aortic Dissection Type A, Transfusions, Platelet Rich Plasma (PRP)","enrollment":250},{"nctId":"NCT06622564","phase":"PHASE3","title":"Decreasing Postoperative Blood Loss and Seizures by Timing of Intravenous Tranexamic Acid 2 Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Hamilton Health Sciences Corporation","startDate":"2025-01-01","conditions":"Bleeding, Surgical Blood Loss, Seizures","enrollment":40},{"nctId":"NCT01914211","phase":"","title":"The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates","status":"WITHDRAWN","sponsor":"Aymen N Naguib","startDate":"2013-07","conditions":"Congenital Heart Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyklokapron"],"phase":"phase_3","status":"active","brandName":"Before CPB Tranexamic Acid","genericName":"Before CPB Tranexamic Acid","companyName":"Hamilton Health Sciences Corporation","companyId":"hamilton-health-sciences-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, reducing blood loss during cardiopulmonary bypass surgery. Used for Reduction of blood loss and transfusion requirements in patients undergoing cardiopulmonary bypass surgery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}